JMS Co

JMS Co Net Debt/Equity

The Net Debt to Equity Ratio of JMS Co (7702.T) as of Nov 3, 2026 is 0.49. In the previous year, Net Debt to Equity Ratio was 0.47 — a change of 4.26% (higher).

Net Debt/Equity

0.49

YoY

4.26%

Last updated:

Net Debt to Equity Ratio of JMS Co is 2026 0.49 . Net Debt to Equity Ratio of JMS Co was 2025 0.47 . It decreases by 4.26% higher compared to the previous year.

The JMS Co Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2019
0.37 JPY
Jan 1, 2020
0.38 JPY
Jan 1, 2021
0.35 JPY
Jan 1, 2022
0.32 JPY
Jan 1, 2023
0.35 JPY
Jan 1, 2024
0.41 JPY
Jan 1, 2025
0.47 JPY
Jan 1, 2026
0.49 JPY
The JMS Co Net Debt/Equity history
YEARNet Debt/EquityYoY
0.49+4.26%
0.47+13.85%
0.41+17.59%
0.35+8.15%
0.32-8.62%
0.35-8.33%
0.38+4.42%
0.37-6.33%
0.39+5.61%
0.37+8.07%
0.34+34.23%
0.26+17.25%
0.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JMS Co stock

Net Debt to Equity Ratio of JMS Co is 0.49 in 2026.

Net Debt to Equity Ratio of JMS Co changed from 0.47 to 0.49, representing a 4.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio JMS Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's JMS Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — JMS Co

All Key Metrics — JMS Co